2. This provision causes some problems in the case of compounds for which authorization may have been granted in one form but which would be equally effective in the form of some other salt or ester. The wording of the regulation is not entirely clear on this point and in the United Kingdom at least it seems that the claim of a supplementary protection certificate may be in the form "X, optionally in the form of a pharmaceutically acceptable salt".
3. Case C-181/95 decided 23 January 1997.
4. The product was a vaccine and the marketing authorization was held by a licensee of inter alia the owner of patents on DNA intermediates used in producing the vaccine.
